NasdaqGS:NBIXBiotechs
Neurocrine Biosciences (NBIX) Stock Slides As Growth Spending Steals Focus
Neurocrine Biosciences just saw its stock drop about 10% to roughly US$166 even though the quarter delivered what many long term holders have wanted most. Revenue for Q2 reached about US$959m, helped by three commercial products working together and a full quarter pro forma sales figure close to US$1b. Non generally accepted accounting principles earnings per share came in at US$2.85, even after folding in the Soleno deal and related costs.
For you as an investor, the headline is simple: the...